Abeona Therapeutics Inc.

As of June 30, 2026, Abeona Therapeutics, Inc. carries a market capitalization of 345.64M, placing it among publicly traded companies globally. Its enterprise value stands at 218.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Abeona Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Abeona Therapeutics, Inc. has 57.23M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 13.19, and the price-to-book ratio stands at 2.70.

These figures are as of June 30, 2026. The EV/Sales ratio of 8.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 218.69M versus a market cap of 345.64M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Abeona Therapeutics, Inc. maintains a current ratio of 6.63, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.52, indicating elevated leverage, while an interest coverage ratio of -24.14 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Abeona Therapeutics, Inc. posted a negative return on equity (ROE) of -43.13, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -29.54, reflecting losses generated across the asset base. The company generates approximately 125,405.41 in revenue per employee across its workforce of 203.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.37 indicates how many times Abeona Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Abeona Therapeutics, Inc. recorded an income tax benefit of -15.41M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -78.30M and -62.89M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Abeona Therapeutics, Inc.'s stock has declined approximately 17.64% over the past 52 weeks. The 50-day moving average sits at 5.47, while the 200-day moving average is 5.50.

Over the twelve months ended June 30, 2026, Abeona Therapeutics, Inc. generated 25.52M in revenue and converted that into -62.89M in net income, yielding earnings per share of -1.13. EBITDA reached -79.93M, while operating income came in at -83.61M.

As of June 30, 2026, Abeona Therapeutics, Inc. holds 146.83M in cash and equivalents against 19.87M in total debt, resulting in a net debt position of -41.24M. Total book value stands at 128.06M, with working capital of 139.77M providing operational flexibility.

Abeona Therapeutics, Inc. produced -76.44M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Abeona Therapeutics, Inc. posted a gross margin of 60.04, reflecting its pricing power and cost economics. The operating margin of -327.64 and net profit margin of -246.42 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -22.71: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.93, meaning Abeona Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Abeona Therapeutics, Inc.'s most recent stock split took place on July 11, 2022 with a 25:1 split ratio.

As of June 30, 2026, Abeona Therapeutics, Inc. has an Altman Z-Score of -2.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.